Outcomes of HER2-positive non-metastatic breast cancer patients treated with anti-HER2 therapy without chemotherapy
Sign Up to like & getrecommendations! Published in 2021 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-021-06115-9
Abstract: Anti-HER2 therapy delivered in the adjuvant setting for breast cancer is given in conjunction with cytotoxic chemotherapy. For HER2-positive (HER2+) patients who cannot tolerate chemotherapy, there is no randomized data regarding the role of anti-HER2… read more here.
Keywords: therapy; her2; her2 therapy; breast cancer ... See more keywords
Targeted therapy: Leveraging ADCC to enhance anti-HER2 therapy
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/nrclinonc.2017.19
Abstract: ...was active in these patients, two-thirds of whom had received prior anti-HER2 therapy Outcomes of patients with HER2+ breast or gastroesophageal cancer are greatly improved with standard anti‐HER2 antibody therapies, principally trastuzumab; however, resistance and… read more here.
Keywords: therapy; anti her2; her2 therapy; cancer ... See more keywords
Clinical characteristics of patients with no evidence of disease (NED) versus residual disease (RES) to anti-HER2 therapy in metastatic breast cancer (MBC): A multi-institutional analysis.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.1034
Abstract: 1034 Background: Anti-HER2 therapy has improved survival in HER2+ MBC. Yet, large patient cohorts with no evidence of disease (NED) with long-term follow up are incompletely described in the literature. We evaluated the clinical characteristics… read more here.
Keywords: mbc; anti her2; disease; her2 therapy ... See more keywords
Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy
Sign Up to like & getrecommendations! Published in 2020 at "PLoS ONE"
DOI: 10.1371/journal.pone.0241775
Abstract: Purpose The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline on HER2 testing in breast cancer permits reclassification of cases with HER2-equivocal results by FISH. The impact of such reclassification is unclear.… read more here.
Keywords: her2 equivocal; anti her2; asco cap; her2 negative ... See more keywords
Value of CT-Based Radiomics in Predicating the Efficacy of Anti-HER2 Therapy for Patients With Liver Metastases From Breast Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.852809
Abstract: Objective This study aims to assess the performance of machine learning (ML)-based contrast-enhanced CT radiomics analysis for predicating the efficacy of anti-HER2 therapy for patients with liver metastases from breast cancer. Methods This retrospective study… read more here.
Keywords: efficacy anti; validation; value; phase ... See more keywords